Managing prices for hospital pharmaceuticals: A successful strategy for New Zealand?

Value in Health

Volumn 8, Issue 3, 2005, Pages 201-208

  Tordoff, June M ^a   Morris, Pauline T ^a   Reith, David M ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Drug costs; Group purchasing; Hospitals; Pharmaceutical preparations; Public

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANALGESIC AGENT; ANESTHETIC AGENT; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; ATRACURIUM; BISPHOSPHONIC ACID DERIVATIVE; CARDIOVASCULAR AGENT; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CENTRAL NERVOUS SYSTEM AGENTS; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; FLUCLOXACILLIN; GASTROINTESTINAL AGENT; IMMUNOMODULATING AGENT; ISOFLURANE; LOCAL ANESTHETIC AGENT; NEUROLEPTIC AGENT; PAMIDRONIC ACID; PENICILLIN DERIVATIVE; PROPOFOL; QUINOLONE DERIVATIVE; SEVOFLURANE; TRAMADOL; UNINDEXED DRUG; VANCOMYCIN;

ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COST; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HEALTH CARE COST; HOSPITAL COST; HOSPITAL PHARMACY; HUMAN; NEW ZEALAND; PRIORITY JOURNAL; PUBLIC HOSPITAL; RURAL AREA; SENSITIVITY ANALYSIS;

EID: 22544468052     PISSN: 10983015     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2005.04040.x     Document Type: Article

References (33)

1. Jacobzone S. Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals. Labour Market and Social Policy-Occasional Papers No. 40. Paris: Organisation for Economic Co-operation and Development, 2000.
2. DeStefino K. Supply and demand: negotiating the prescription drug labyrinth to reduce costs. Benefits Q 2003;19:30-7.
3. Freemantle N, Bloor K. Lessons from international experience in controlling pharmaceutical expenditure. I: influencing patients. BMJ 1996;312:1469-71.
4. Bloor K, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure. II: influencing doctors. BMJ 1996;312:1525-7.
5. Bloor K, Maynard A, Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure. III: regulating industry. BMJ 1996;313:33-5.
6. Maynard A, Bloor K. Dilemmas in regulation of the market for pharmaceuticals. Health Aff 2003;22:31-41.
7. Kanavos P. Financing pharmaceuticals in transition economies. Croat Med J 1999;40:244-59.
8. Brae R, McNee W, Moore D. Managing pharmaceutical expenditure while increasing access. The pharmaceutical management agency (PHARMAC) experience. Pharmacoeconomics 1999;16:649-60.
9. Eopez Bastida J, Mossialos E. Pharmaceutical expenditure in Spain: cost and control. Int. J Health Serv 2000;30:597-616.
10. Department of Health. The Pharmaceutical Price Regulation Scheme: Report to Parliament. London: Department of Health, 1996.
11. Ioannides-Demos LL, Ibrahim JE, McNeil JJ. Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes. Pharmacoeconomics 2002;20: 577-91.
12. Campbell KG. The combined hospital boards' drug purchasing scheme. NZ Hosp 1980;32:23-7.
13. Lemon ABW. Group purchasing and shared regional services. Hosp Mat Manage Q 1984;6: 52-7.
14. Huff-Rousselle M, Burnett F. Cost containment through pharmaceutical procurement: a carribean case study. Inter J Health Plann Mange 1996;11: 135-57.
15. Curds S, Mounsey C. Pharmacy procurement: the contracting process for generic drugs. Hosp Pharm 1998;5:151-4.
16. Bae JP, Justice PG. Pharmacy Benefit Management contracting: an assessment from a recent public sector procurement experience. J Health Care Finance 2002;29:49-56.
17. Pharmaceutical Management Agency. Annual Review. Wellington, New Zealand: PHARMAC, 2002.
18. Centers for Medicare and Medicaid Services Baltimore. National health expenditure amounts and average percentage change by type of expenditure: selected calendar years 1980-2012. 2001. WWW document: Available from: http://cms.hhs.gov/statistics/nhe/projections-2002/t2.asp [Accessed March 6, 2004].
19. Audit Commission, Primary Care Prescribing. A bulletin for primary care trusts. London, 2003. WWW document: Available from: http://www. audit-commission.gov.uk/index.asp [Accessed March 6, 2004).
20. Pharmaceutical Benefits Scheme. Prescription expenditure twelve-month data (1999-2001). WWW document: Available from: http://www. health.gov.au/pbs/ general/pubs/pbbexp/index.htm [Accessed March 6, 2004].
21. Pharmaceutical Management Agency. Statement of intent. 2003. WWW document: Available from: http://www.pharmac.govt.nz/pdf/SOI2004/.pdf [Accessed February 23, 2004].
22. Pharmaceutical Management Agency. National hospital pharmaceutical strategy final version. 2002.
23. Pharmaceutical Management Agency. New Zealand pharmaceutical schedule. Section H for hospital pharmaceuticals. 2004. WWW document: Available from: http://www.pharmac.govt.nz/pdf/SectionH.pdf [Accessed February 21, 2004].
24. Tordoff J, Norris P, Kennedy J, Reith D. Quality use of medicines activities in New Zealand hospitals from 2000 to 2002. NZ Med J 2005;118(1208):U1259.
25. New Zealand Health Information Service. Public Hospital Data from National Minimum Data Set, 1 July 2002 to 30 June 2003. Wellington, New Zealand: Ministry of Health, 2004.
26. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index 2004. WWW document: Available from: http://www.whocc.no/atcddd/ [Accessed February 21, 2004].
27. Anonymous. Auckland: Australasian Drug Information Services. New Ethicals Catalogue 2001; 38:94.
28. Cannon K, Gebhart F. Pharmacy debates pluses, minuses of large GPOs. Hosp Pharm Rep 1997; 11:67-70.
29. Le Pen C. Drug pricing and reimbursement in France. Towards a new model? Pharmacoeconomics 1996;10(Suppl. 2):S26-36.
30. Mapelli V, Lucioni C. Spending on pharmaceuticals in Italy: macro constraints with local autonomy. Value in Health 2003;6(Suppl. 1):S31-45.
31. Department of Health. Faster access to modern treatment; how NICE appraisal will work. Leeds. NHS Executive. 1999. WWW document: Available from: http://www.nice.org.uk/article.asp?a=290 [Accessed March 6, 2004].
32. Pharmaceutical Management Agency. Annual Review. Wellington, New Zealand: PHARMAC, 2003.
33. Management Sciences for Health Procurement of drugs in Managing Drug Supply. The Selection, Procurement, Distribution, and Use of Pharmaceuticals. West Hartford, CT: Kumarian Press, 1997.